Osmanias manufacturing facility receives FDA pre-approval inspection
Oasmia Pharmaceutical AB, a Swedish pharmaceutical company, announces successful FDA pre-approval inspection of its manufacturing. It is about is manufacturing unit at Uppsala, Sweden. It has successfully passed a pre-approval inspection by the US Food and Drug Administration (FDA).
The firm considers this as a significant milestone in our efforts and accomplishments to bring their products to the market. The company announced this with great pleasure about the fact that the FDA has confirmed their compliance with the current good manufacturing practice (cGMP) standards. They are also pleased that their manufacturing capability and commitment to provide products are considered of high quality. The company's product development aims to develop and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics.
